Revolution Medicines (RVMD) Change in Accured Expenses (2019 - 2026)

Revolution Medicines' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1180.63% year-over-year to -$16.7 million; the TTM figure through Mar 2026 stood at $94.0 million (up 109.81% YoY), while the FY2025 annual figure was $112.3 million, up 410.65% from the prior year.
• Change in Accured Expenses was -$16.7 million for Q1 2026 at Revolution Medicines, down from $54.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $54.6 million in Q4 2025 to a low of -$21.3 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $7.9 million across 5 years, with a median of $7.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses jumped 685.1% in 2023, then plunged 1180.63% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at -$3.0 million in 2022, then slumped by 112.1% to -$6.3 million in 2023, then soared by 390.86% to $18.3 million in 2024, then soared by 198.42% to $54.6 million in 2025, then slumped by 130.66% to -$16.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$16.7 million (Q1 2026), $54.6 million (Q4 2025), and $45.3 million (Q3 2025), per Business Quant data.